113 related articles for article (PubMed ID: 22939958)
1. Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer.
Rahman M; Nakayama K; Rahman MT; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Miyazaki K
Hum Pathol; 2013 Jan; 44(1):103-9. PubMed ID: 22939958
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma.
Zhang ZM; Xiao S; Sun GY; Liu YP; Zhang FH; Yang HF; Li J; Qiu HB; Liu Y; Zhang C; Kang S; Shan BE
Int J Gynecol Cancer; 2014 Mar; 24(3):534-40. PubMed ID: 24557437
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
4. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas.
Nakayama K; Rahman MT; Rahman M; Nakamura K; Ishikawa M; Katagiri H; Sato E; Ishibashi T; Iida K; Ishikawa N; Kyo S
Int J Oncol; 2016 Feb; 48(2):506-16. PubMed ID: 26647729
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 and p53 expressions in endometrial cancer.
Jeon YT; Kang S; Kang DH; Yoo KY; Park IA; Bang YJ; Kim JW; Park NH; Kang SB; Lee HP; Song YS
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1538-42. PubMed ID: 15342458
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-I receptor and PTEN protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, microsatellite instability status, and outcome.
Peiró G; Lohse P; Mayr D; Diebold J
Am J Clin Pathol; 2003 Jul; 120(1):78-85. PubMed ID: 12866376
[TBL] [Abstract][Full Text] [Related]
7. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.
Wiegand KC; Lee AF; Al-Agha OM; Chow C; Kalloger SE; Scott DW; Steidl C; Wiseman SM; Gascoyne RD; Gilks B; Huntsman DG
J Pathol; 2011 Jul; 224(3):328-33. PubMed ID: 21590771
[TBL] [Abstract][Full Text] [Related]
8. Expression of Ret finger protein correlates with outcomes in endometrial cancer.
Tsukamoto H; Kato T; Enomoto A; Nakamura N; Shimono Y; Jijiwa M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
Cancer Sci; 2009 Oct; 100(10):1895-901. PubMed ID: 19650860
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome.
Ferrandina G; Legge F; Ranelletti FO; Zannoni GF; Maggiano N; Evangelisti A; Mancuso S; Scambia G; Lauriola L
Cancer; 2002 Aug; 95(4):801-7. PubMed ID: 12209724
[TBL] [Abstract][Full Text] [Related]
10. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium.
Fadare O; Gwin K; Desouki MM; Crispens MA; Jones HW; Khabele D; Liang SX; Zheng W; Mohammed K; Hecht JL; Parkash V
Mod Pathol; 2013 Aug; 26(8):1101-10. PubMed ID: 23524907
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
[TBL] [Abstract][Full Text] [Related]
12. Value of T cell receptor gamma alternate reading frame protein and keratin 5 in endometrial carcinoma.
Zhao LJ; Li XP; Qi WJ; Wang JL; Wei LH
Chin Med J (Engl); 2013 Nov; 126(22):4260-4. PubMed ID: 24238509
[TBL] [Abstract][Full Text] [Related]
13. Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.
Trovik J; Wik E; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; Njolstad TS; ; Vandenput I; Amant F; Akslen LA; Salvesen HB
Clin Cancer Res; 2011 May; 17(10):3368-77. PubMed ID: 21242118
[TBL] [Abstract][Full Text] [Related]
14. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
16. Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma.
Zhang L; Wang C; Yu S; Jia C; Yan J; Lu Z; Chen J
Technol Cancer Res Treat; 2018 Jan; 17():1533034618754475. PubMed ID: 29486633
[TBL] [Abstract][Full Text] [Related]
17. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic Association and Prognostic Value of Microcystic, Elongated, and Fragmented (MELF) Pattern in Endometrial Endometrioid Carcinoma.
Kihara A; Yoshida H; Watanabe R; Takahashi K; Kato T; Ino Y; Kitagawa M; Hiraoka N
Am J Surg Pathol; 2017 Jul; 41(7):896-905. PubMed ID: 28418994
[TBL] [Abstract][Full Text] [Related]
19. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
20. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]